KGW-TV
September 12, 2024
In a wide-ranging, two-part interview, Brian Druker, M.D., discusses highlights from his career, advancements from the OHSU Knight Cancer Institute, and how artificial intelligence will play a role in the future of cancer research. When asked about Gleevec, the drug he developed, he says: “But the wealth that I have is that at least once a week I get an email in my inbox from a patient who has benefited from this medication, and what a remarkable reward to get an email at the end of a long week that said, 'Thank you for this drug, and here's all the incredible things I've done over the last decade.'"